
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Paris - Dermatologists may find yet another use for extracorporeal photopheresis (ECP), as it seemingly treats atopic dermatitis, according to Gerd Plewig, M.D.